{ "version": "20260604_core_validation_v45", "red_warning": false, "duplicate_flags": [], "position": "OligoVigil should be framed as a safety/off-target evidence and provenance resource, not as a broad RNA therapeutics catalog, siRNA efficacy database, or complete sequence/modification catalog.", "defensible_claims": [ { "claim": "Safety/off-target first", "defense": "The core release records are toxicity and off-target evidence, with A/B/C grading and source-localized provenance." }, { "claim": "Benchmark-ready evidence release", "defense": "Grade A/B records have deterministic reference splits and task cards; efficacy-focused comparators do not provide the same safety/off-target benchmark framing." }, { "claim": "License-aware curation boundary", "defense": "The portal exposes derived annotations, source links, reuse categories, and download checksums without redistributing raw article text." }, { "claim": "Honest sequence/modification roadmap", "defense": "Sequence, chemistry, and dose fields are exposed as source-verifiable curation packets rather than inflated as completed coverage." } ], "do_not_claim": [ "Do not claim to be the most complete RNA therapeutics catalog; theRNA is broader.", "Do not claim primary siRNA efficacy novelty; siRNAEfficacyDB and CMsiRNAdb are closer on efficacy.", "Do not claim complete sequence/modification coverage until P0 core field curation is completed.", "Do not claim release-row false-accept / false-reject error rates before the 500-row second-review packet is filled and adjudicated (inter-curator Cohen kappa is separately claimed from the completed 100-row KAPPA-2 study: 0.42 drop-abstain / 0.34 collapse-abstain)." ], "closest_work_rows": [ { "resource": "theRNA", "venue_year": "NAR 2026", "doi_pmid": "DOI:10.1093/nar/gkaf1064; PMID:41171135", "primary_scope": "broad functional RNA therapeutics across RNA modalities and disease applications", "sequence_or_molecule": "yes", "chemical_modification": "partial", "delivery": "partial", "target_disease": "yes", "efficacy": "yes", "toxicity": "not_core", "offtarget": "not_core", "provenance_audit": "not_primary", "license_boundary": "unclear_from_public_record", "downloads_or_api": "web_resource", "benchmark_splits": "not_primary", "overlap_risk": "medium", "oligovigil_position": "Do not claim broad RNA therapeutics catalog novelty; OligoVigil should position as safety/off-target evidence with audit, downloads, and benchmark-ready release." }, { "resource": "siRNAEfficacyDB", "venue_year": "IET Systems Biology 2024", "doi_pmid": "DOI:10.1049/syb2.12102; PMID:39541343", "primary_scope": "experimentally supported siRNA efficacy database", "sequence_or_molecule": "yes", "chemical_modification": "no", "delivery": "no", "target_disease": "target_gene_and_cell_context", "efficacy": "yes", "toxicity": "no", "offtarget": "no", "provenance_audit": "limited", "license_boundary": "open_article_cc_by", "downloads_or_api": "database_download", "benchmark_splits": "not_primary", "overlap_risk": "medium", "oligovigil_position": "Do not claim primary siRNA efficacy novelty; OligoVigil excludes efficacy as its main contribution and focuses on safety/off-target evidence." }, { "resource": "CMsiRNAdb", "venue_year": "BMC Bioinformatics 2026", "doi_pmid": "DOI:10.1186/s12859-025-06359-y; PMID:41484819", "primary_scope": "chemically modified siRNA silencing efficiency from patents", "sequence_or_molecule": "yes", "chemical_modification": "yes", "delivery": "partial", "target_disease": "target_gene_and_cell_context", "efficacy": "yes", "toxicity": "not_primary", "offtarget": "limited", "provenance_audit": "curated_but_efficacy_oriented", "license_boundary": "article_cc_by_nc_nd; patent_reuse_requires_care", "downloads_or_api": "database_download_and_prediction", "benchmark_splits": "not_primary", "overlap_risk": "high", "oligovigil_position": "Strongest adjacent work for sequence/modification/dose fields; OligoVigil must avoid claiming complete chemistry coverage until P0 field curation is verified." }, { "resource": "siRNAmod", "venue_year": "RNA Biology 2016", "doi_pmid": "PMCID:PMC4730238", "primary_scope": "experimentally validated chemically modified siRNAs", "sequence_or_molecule": "yes", "chemical_modification": "yes", "delivery": "no", "target_disease": "target_gene_and_cell_context", "efficacy": "yes", "toxicity": "no", "offtarget": "limited", "provenance_audit": "limited", "license_boundary": "open_pmc_article", "downloads_or_api": "web_resource", "benchmark_splits": "not_primary", "overlap_risk": "medium", "oligovigil_position": "Older chemistry/efficacy comparator; reinforces that OligoVigil novelty is not chemical-modification cataloging alone." }, { "resource": "CRISPRoffT", "venue_year": "NAR 2025", "doi_pmid": "not_in_core_scope", "primary_scope": "CRISPR/Cas off-target database", "sequence_or_molecule": "guide_rna", "chemical_modification": "no", "delivery": "no", "target_disease": "target_context", "efficacy": "no", "toxicity": "no", "offtarget": "yes", "provenance_audit": "resource_specific", "license_boundary": "web_resource", "downloads_or_api": "web_resource", "benchmark_splits": "not_primary", "overlap_risk": "low", "oligovigil_position": "Scope exclusion; CRISPR guide off-target data are not part of OligoVigil core." }, { "resource": "DrugBank", "venue_year": "ongoing", "doi_pmid": "licensed_database", "primary_scope": "drug knowledgebase", "sequence_or_molecule": "drug_level", "chemical_modification": "partial", "delivery": "partial", "target_disease": "yes", "efficacy": "partial", "toxicity": "partial", "offtarget": "no", "provenance_audit": "curated_database", "license_boundary": "licensed_restricted", "downloads_or_api": "licensed_api", "benchmark_splits": "no", "overlap_risk": "low", "oligovigil_position": "Link-out only unless license permits redistribution; not a safety/off-target oligo evidence benchmark resource." }, { "resource": "TTD", "venue_year": "ongoing", "doi_pmid": "licensed_or_terms_review_needed", "primary_scope": "therapeutic target/drug annotations", "sequence_or_molecule": "drug_target_level", "chemical_modification": "partial", "delivery": "no", "target_disease": "yes", "efficacy": "partial", "toxicity": "partial", "offtarget": "no", "provenance_audit": "curated_database", "license_boundary": "license_review_needed", "downloads_or_api": "web_resource", "benchmark_splits": "no", "overlap_risk": "low", "oligovigil_position": "Useful target/drug comparator but not a release-grade oligo safety/off-target evidence benchmark." }, { "resource": "OligoVigil", "venue_year": "current_presubmission", "doi_pmid": "local_presubmission", "primary_scope": "curator-reviewed ASO/siRNA safety and off-target evidence with provenance and benchmark splits", "sequence_or_molecule": "incomplete_curation_track", "chemical_modification": "incomplete_curation_track", "delivery": "incomplete_curation_track", "target_disease": "contextual", "efficacy": "not_primary", "toxicity": "core", "offtarget": "core", "provenance_audit": "core_release_audit", "license_boundary": "derived_annotations_only", "downloads_or_api": "csv_api_zip_agent_access", "benchmark_splits": "downloadable_A_B_reference_splits", "overlap_risk": "self", "oligovigil_position": "Defensible only if framed as evidence-grade safety/off-target provenance plus benchmark splits; sequence/modification/dose curation must be presented as an explicit upgrade track." } ] }